In Vivo and Logic-Gated CAR-T Therapies Garner Over $700M in Funding Within Two Days

T-CURX

On December 17, T-CURX announced the successful completionSeries A First Round Financing of 20 Million US DollarsThis round of financing was jointly participated by investors from Europe and Asia, and the funds obtained will be used to accelerate the company's CAR-T therapy based on a non-viral technology platform for acute myeloid leukemia.（AML）in the clinical development of solid tumors and further advance its proprietary in vivo CAR-T technology platform.

T-CURX's proprietary technology includes multiple technical platforms that address the current limitations of CAR-T cell therapy:

1. Through based onSleeping Beauty Transposon Combined with Innovative mRNA/Microcircle DNA TechnologyThe CAR-T cell engineering approach achieves higher scalability and reduces production costs;

2. A completely new matching optimization technology that optimizes the spacer regions in the CAR structure for optimal efficacy;

3. Novel Lipid Nanoparticles（LNP）Delivery technology that delivers transposon vector components into patient T cells via transposon-LNPs, enabling a highly scalable and patient-centered point-of-care CAR-T preparation solution, and potentially usable in the future for in vivo direct generation of CAR-T cell therapeutic strategies.

Byterna Therapeutics

On December 15, Byterna Therapeutics completedAngel+ Round Financing. This round of financing was exclusively invested by EF BioVentures, and the funds will be used to accelerate the advancement.Circular mRNA（cmRNA）In-body CAR-T Pipeline BR101The IIT clinical study. It is worth noting that the company had just completedTens of Millions of RMB in Angel Round Financing。

Since its establishment, Byterna Therapeutics has focused on the research and development of in vivo CAR-T drugs, establishing a globally leading circular mRNA new drug development platform. Byterna Therapeutics has achieved technological breakthroughs in high-barrier areas such as seamless and efficient cyclization, AI sequence design, circular mRNA chemical modification, in vivo T-cell targeted delivery, and circular mRNA CAR design and evaluation, and has applied for more than 10 domestic and international patents.Built the three major technology platforms: Byterna.AI × cmCAR × CellectLNP, and has laid out multiple in vivo CAR-T pipelines. The core pipeline has completed key preclinical trial verification and is rapidly advancing into clinical research.

Link Cell Therapies

On December 15, Link Cell Therapies announced the completion$60 Million Series A FinancingThis round of financing was led by Johnson & Johnson through its corporate venture capital arm, Johnson & Johnson Innovation-JJDC, Inc., with participation from Samsara BioCapital, Sheatree Capital, Wing Venture Capital, and other new strategic and financial investors.

Link Cell Therapies independently developedAND Logic Gate Control Technology, enabling precise and safe targeting of multiple co-expressed antigens on the surface of cancer cells. Such targeted antigens are either absent or exhibit minimal overlap in normal healthy tissues.The LINK CAR-T cells corresponding to this technology are equipped with a dual CAR structure.The two CAR structures use SLP-76 and LAT, two TCR signaling molecules, as activation domains. Only when both target antigens simultaneously bind to their corresponding CAR structures can a complete activation domain be assembled, thereby initiating the cytotoxic function of CAR-T cells.

Link Cell Therapies Core Project LNK001 Focuses on Renal Cell Carcinoma（RCC）Treatment, the current R&D progress is smooth, and the planSubmit an Investigational New Drug Application and Initiate Phase I Clinical Trials in 2026The drug targets two antigens that are highly co-expressed in most RCC tumors. It was designed to achieve tumor-specific efficacy while avoiding non-tumor toxicities commonly associated with targeted therapies — toxicities that have previously limited the effectiveness of experimental single-antigen targeted therapies.

Its second project targets colorectal cancer, with plans to complete candidate drug screening by 2026 and initiate human clinical research in 2027. Additionally, the company has multiple CAR-T therapy projects for solid tumors and hematological cancers in the early stages of development, which will be advanced through internal research or collaboration models moving forward.

The Emergence of Three Financing Events Within Two Days: Reflecting Not Only the Global Capital Heat in the CAR-T Field, but Also the Core Development Trend Towards "Bottleneck Breakthroughs"

Exciting Live Broadcast Preview

Press and hold to scan the QR code and participate immediately ↓

Recommendation 1

December 30, 15:00-16:00

New Breakthrough in Tumor Immunology: Automation Technology Advances the Industrialization of DC Cells

Statement:This article aims to convey industry development information and explore the frontier progress of biopharmaceuticals. The content of the article represents the author's viewpoint and does not represent the position of Eureka, nor does it constitute any value judgment, investment advice, or medical guidance. If necessary, please consult a professional for investment or visit a正规 hospital for medical advice.

Copyright Statement:Welcome to share the article on your personal Moments. Unauthorized reprinting by media or organizations in any form to other platforms is prohibited. For reprinting, please leave a message under the article to obtain authorization.

Cover image source: internet. If there is any copyright infringement, please contact us for removal.

DianDian "Share”、“Like" and "In Progress”

Give me a little charge~